Cargando…

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling

Most tumors develop resistance to targeted cancer drugs, even though these drugs have produced substantial clinical responses. Here we established anaplastic lymphoma kinase (ALK)‐positive drug‐resistant lung cancer cell lines, which are resistant to ceritinib (LDK378). We found that ceritinib treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yi, Yang, Yi, Xu, Yunhua, Lu, Shun, Jian, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377386/ https://www.ncbi.nlm.nih.gov/pubmed/28396832 http://dx.doi.org/10.1002/2211-5463.12162

Ejemplares similares

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines
por: Gwanmesia, Patricia Mambou, et al.
Publicado: (2009)

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
por: McGivern, Niamh, et al.
Publicado: (2017)

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)
por: Huang, R Y-J, et al.
Publicado: (2013)

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
por: Oswald, Ailsa J., et al.
Publicado: (2023)

Mechanisms of disease-modifying effect of saracatinib (AZD0530), a Src/Fyn tyrosine kinase inhibitor, in the rat kainate model of temporal lobe epilepsy
por: Sharma, Shaunik, et al.
Publicado: (2021)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial
por: van Dyck, Christopher H., et al.
Publicado: (2019)

Synergistic effect of STAT3-targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo
por: Liu, Qingjun, et al.
Publicado: (2019)

Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023)

Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
por: Baird, Kristin, et al.
Publicado: (2020)

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)

The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
por: Xiao, Juanjuan, et al.
Publicado: (2022)

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis
por: Wang, Yongfeng, et al.
Publicado: (2016)

Correction: The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
por: Moharram, Sausan A., et al.
Publicado: (2019)

Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
por: Filipponi, Doria, et al.
Publicado: (2022)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK ‐rearranged lung cancer
por: Talwelkar, Sarang S., et al.
Publicado: (2023)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
por: Shrestha, N., et al.
Publicado: (2019)

Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
por: Paliouras, Athanasios R, et al.
Publicado: (2020)

Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2021)

Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017)

Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition
por: Kerner, Gerald S. M. A., et al.
Publicado: (2016)

ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
por: Schläfli, Anna M., et al.
Publicado: (2021)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2022)

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment
por: Dawson, John C., et al.
Publicado: (2021)

AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
por: Zhang, Kai-li, et al.
Publicado: (2019)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors
por: Sato, Hiroki, et al.
Publicado: (2022)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Tree-in-bud Pattern in ALK-positive Lung Adenocarcinoma
por: Shiroyama, Takayuki, et al.
Publicado: (2020)

Patient-led advocacy in ALK-positive lung cancer
por: Barton, Colin, et al.
Publicado: (2023)

SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
por: Zhu, Eliot Y., et al.
Publicado: (2022)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aljb2jd3lr6qlu5s0frqlk8v5r